On 4^th of March, after the closure of markets, an announcement is expected from Salix Pharmaceuticals Ltd.(NASDAQ:SLXP) that the company would most likely be divulging its financial results of Q4 of the year 2014. The market shares of the company’s major drug Xifaxan and other such drugs have been experiencing a noticeable downfall, due to which the its overall revenue has been affected. Owing to this reason, analysts have also predicted that the company’s generated income would be less in comparison with its previous results.

However, Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) hoards many surprises in itself and has successfully managed to prove 5 out of 9 analysts’ estimates to be in the negative and has amounted to a figure of $15.39. It is very possible that the when the financial results of this latest quarter are finally made public, Salix pharmaceuticals Ltd. (NASDAQ:SLXP) might turn out to be keeping in line with its trend.

According to the estimated report presented by the analysts, it is expected that for the fourth quarter of fiscal year 2014, the generated income of Salix Pharmaceuticals Ltd.(NASDAQ:SLXP) would be $187.9 million. This revenue reflects a downfall of 21% YOY which indeed a great amount, particularly when studied in comparison with revenues of the previous years. This is obvious in the statistics of the fourth quarter of fiscal year 2013 which delineate revenue of $257.6 million. Moreover, the revenue of fourth quarter wouldn’t just be lower in comparison with that of the previous fiscal year; rather it will also be less than the generated income of the previous three quarters.

Despite this slow progression of growth which is expected in the fourth quarter; there is a rising speculation that Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) will come across brighter prospects and this will be reflected in the results of the year 2014. It is very likely that the adjusted EPS would witness an increase of $3.84 in the year 2014. This increase in turn would reflect an increased YOY. In contrary to these expected results, the previous year saw a decline in its YOY by 25.4%.

Not only does Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) have a brighter picture painted in future, Sanofi also shares in these positive prospects. There are expectations abroad regarding the increase in its EPS of about $5.17 in the year 2014. This increase would consequently reflect a growth in YOY of about 1.5%.  This increase in YOY is in contrast to the downfall in its YOY of approximately 5.7%, in fiscal year 2013. However, the positive results of this year would most probably compensate previous year’s results.

Yet, things do not appear to be so good for Salix’s Xifaxan. Wall Street report gives an estimate of $77.4 million revenue in the fourth quarter. This figure represents a decline in YOY of approximately 56%. Side by side, the estimate also claims that for the entire year, its sales would be on a standstill, i.e. at $ 492.1 million.

Unidentified sources claim that negotiations between Allergan Inc. (NYSE:AGN) and Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) went cold because Salix demanded more than what Allergan was willing to pay for the deal. Even though discussions are open again but it is too soon to say whether some agreement will be made between the two parties or not; therefore no immediate result of these discussions should be expected at this point. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) stock ended yesterday’s trading at a value of $10 billion.

Allergan Inc. (NYSE:AGN)’s main goal for making an offer to Salix was to save itself from hostile takeover from Valeant. This acquisition will require Valeant to spend more money in order to acquire Allergan, which might force Valeant to rethink its decision.

Valeant is not the only company interested in Allergan Inc. (NYSE:AGN). Actavis Plc. also expressed an interest in acquiring Allergan back in August. The offer made by Actavis was as unappealing to Allergan as the one made by Valeant. Actavis also believes that this acquisition can help them grow in the pharmaceutical sector.

Allergan Inc. (NYSE:AGN), Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) and Actavis representative refused to comment on their current position in the matter.

David Pyott, CEO of Allergan Inc. (NYSE:AGN) said that Allergan currently has many options when it comes to acquisitions.

Valeant sought help from Pershing Square Capital Management LP’s Bill Ackman back in April to have its offer worth $54 billion accepted by Allergan; the $54 billion was to be paid in cash and stock. However Allergan turned the offer down after which Valeant made two more offers that were higher than the initial one.

Allergan Inc. (NYSE:AGN)’s stock went up by 50% in 2014. The closing value of its shares on Monday was $166.12, which made its total market value worth $51 billion. On the other hand Salix went up by 78% in 2014; the company is currently in the process of a merger with Cosmo Pharmaceuticals SpA – an Italian Drugmaker company.

Cosmo’s CFO Chris Tanner said that they have no idea about the discussions going on between Allergan and Salix. Cosmo’s merger with Salix may come to a halt if the deal between Salix and Allergan gets finalized.

Tanner believes that Cosmo’s merger with Salix will be a good move for the company; however at the moment they are not letting the current scenario affect their day to day operations.

Allergan Inc. (NYSE:AGN) stock opened today at a value of $166.95 and at 10:53 am EDT was trading at a value of $170, after taking a jump up by 2.33%. The stock’s market cap is 50.50 B whereas its inst. ownership is 94%. Allergan Inc. (NYSE:AGN)’s range over 52 weeks has been between 88.34 and 174.49.

The company announced study results Tuesday morning that a statistically significant greater proportion of subjects treated with rifaximin responded positively to repeat treatment in the TARGET 3 Phase 3 study.

The stock opened on Tuesday at $138.30, and set a new high for the year.

The company is also awaiting the Food and Drug Administration’s decision on ruconest, a hereditary angioedema drug. Salix acquired the drug when it purchased Santarus for $2.6 billion. Experts say there is a 50-50 chance that it will be approved.

However, today, Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) reported successful outcomes of Target 3. The company claimed to the press that a statistically larger number of patients with IBS-D showed response to the repeat treatment of rifaximin 550 mg TID, as opposed to those treated with the placebo. During the PEP, Primary Evaluation Period, which is a four week follow-up period without any treatment, the subjects were assessed based on their stool consistency and abdominal pains. Thanks to the successful outcome of Target 3, the shares of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) increased 13%, which was a new high for the company.

Stratasys, Ltd. (NASDAQ:SSYS) provides equipment for 3-D printing and material that allows one to create physical items from the digital data available. The systems offered by the company span a wide range – you can either avail their desktop 3-D printing machines or entire production systems. On July 1^st, 2014, Stratasys, Ltd’s (NASDAQ:SSYS) stocks for 3-D Printing were seeing nothing but rise. This was all thanks to the reports that claimed that these printers can be potentially used in the field of medicine.

Agenus Inc (NASDAQ:AGEN) is a company that specializes in the discovery and development of immunotherapeutics. Currently, the company is in the course of performing Phase II trials on patients of glioblastoma multiforme or GBM. GBM is a very aggressive and most common brain tumor. Its treatment involves surgery, radio –therapy and chemo-therapy. The patients were recently diagnosed with GBM. They were provided standard care treatment and were given the trial drug Agenus Prophage, the autologous vaccine for cancer. This study is open-label and involves the collaboration of multiple institutions. It was a big leap towards success for Agenus Inc when the results of the study showed that the patients who were treated with the cancer vaccine were expected to live two times as much as their expected lifetime. Cancer frequently kills its patients within a year. However, the single-arm, Phase II study has shown that about half of the treated patients lived up to two years, which is a highly encouraging result. Consequently, Agenus Inc (NASDAQ:AGEN) gained 10.98% after the results of the study were proclaimed.

Also, the study shows that the treated patients have an average survival of 24 months. Almost 33% of the patients are still kicking after 2 years. The company is keeping their tracks for survival.